Worth reading
35Immaterial
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
40000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of stock acquisition rights with an exercise price adjustment clause
発行・処分する株式数
40,000 new shares (delivered in July 2026)
発行済株式総数
Exercise ratio subject to exercise restrictions: 0.20% (40,000 shares delivered across all series / 19,196,700 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥303.3 on 10 July 2026 and ¥280.8 on 21 July 2026. Adjustment provisions apply. The adjustment floor was Not disclosed
Number of Stock Acquisition Rights
Exercise ratio against the total number issued: 0.51%. 400 exercised during the month, 76,103 unexercised at the end of the preceding month and 75,703 unexercised at month-end
Basis for determining the amount to be paid
The exercise price was ¥303.3 on 10 July 2026 and ¥280.8 on 21 July 2026. The calculation basis, adjustment rate and floor were Not disclosed
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financing
Development Promotion Stock Acquisition Rights for docirbrutinib (AS-1763) with Exercise Price Adjustment Clause, issued on 17 February 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | 40,000 new shares (delivered in July 2026) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.20% (40,000 shares delivered across all series / 19,196,700 listed shares as of the payment date for the issuance) |
| Basis for determining the amount to be paid | The exercise price was ¥303.3 on 10 July 2026 and ¥280.8 on 21 July 2026. The calculation basis, adjustment rate and floor were Not disclosed |
| Exercise price | ¥303.3 on 10 July 2026 and ¥280.8 on 21 July 2026. Adjustment provisions apply. The adjustment floor was Not disclosed |
| Number of Stock Acquisition Rights | Exercise ratio against the total number issued: 0.51%. 400 exercised during the month, 76,103 unexercised at the end of the preceding month and 75,703 unexercised at month-end |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions. |
| Most recent equity financing | Development Promotion Stock Acquisition Rights for docirbrutinib (AS-1763) with Exercise Price Adjustment Clause, issued on 17 February 2026 |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This reports the monthly exercise status in July 2026 of the stock acquisition rights issued on 17 February 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.